Magnetar Financial LLC bought a new stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 16,982 shares of the company's stock, valued at approximately $408,000.
Other hedge funds have also made changes to their positions in the company. Vestal Point Capital LP purchased a new position in shares of Vera Therapeutics during the fourth quarter worth about $45,462,000. Integral Health Asset Management LLC raised its stake in Vera Therapeutics by 130.0% during the 4th quarter. Integral Health Asset Management LLC now owns 1,150,000 shares of the company's stock valued at $48,634,000 after acquiring an additional 650,000 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in Vera Therapeutics by 8.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,754,832 shares of the company's stock worth $114,212,000 after acquiring an additional 377,783 shares during the period. Paradigm Biocapital Advisors LP lifted its position in Vera Therapeutics by 31.0% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 1,437,339 shares of the company's stock worth $60,785,000 after acquiring an additional 340,488 shares during the period. Finally, T. Rowe Price Investment Management Inc. grew its stake in shares of Vera Therapeutics by 18.4% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 1,675,367 shares of the company's stock valued at $40,243,000 after purchasing an additional 260,188 shares during the last quarter. Institutional investors and hedge funds own 99.21% of the company's stock.
Vera Therapeutics Price Performance
VERA stock traded up $2.29 during trading on Friday, reaching $24.19. 2,747,955 shares of the company were exchanged, compared to its average volume of 1,781,418. The company has a debt-to-equity ratio of 0.16, a quick ratio of 17.03 and a current ratio of 17.03. The stock's 50 day moving average price is $22.19 and its 200 day moving average price is $23.31. Vera Therapeutics, Inc. has a 52-week low of $18.53 and a 52-week high of $51.61. The company has a market cap of $1.54 billion, a P/E ratio of -6.76 and a beta of 1.17.
Vera Therapeutics (NASDAQ:VERA - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.38). During the same quarter in the prior year, the firm earned ($0.62) EPS. As a group, analysts predict that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.
Analysts Set New Price Targets
VERA has been the subject of several analyst reports. JPMorgan Chase & Co. cut their price target on Vera Therapeutics from $56.00 to $53.00 and set an "overweight" rating for the company in a research note on Thursday, August 7th. Guggenheim reissued a "buy" rating on shares of Vera Therapeutics in a research note on Tuesday, June 3rd. Wolfe Research restated a "peer perform" rating on shares of Vera Therapeutics in a research report on Monday, August 4th. HC Wainwright restated a "buy" rating and issued a $85.00 target price (up previously from $75.00) on shares of Vera Therapeutics in a research note on Monday, June 2nd. Finally, Scotiabank reiterated an "outperform" rating on shares of Vera Therapeutics in a research note on Tuesday, June 3rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat, Vera Therapeutics has an average rating of "Moderate Buy" and an average price target of $63.00.
Read Our Latest Stock Report on Vera Therapeutics
Insiders Place Their Bets
In other news, Director Patrick G. Enright acquired 209,393 shares of the company's stock in a transaction that occurred on Monday, June 23rd. The stock was purchased at an average cost of $20.87 per share, with a total value of $4,370,031.91. Following the purchase, the director directly owned 3,569,522 shares of the company's stock, valued at approximately $74,495,924.14. This trade represents a 6.23% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. 16.30% of the stock is owned by insiders.
Vera Therapeutics Company Profile
(
Free Report)
Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.
Recommended Stories

Before you consider Vera Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vera Therapeutics wasn't on the list.
While Vera Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.